According to Cancer.gov, when compared to white men, black men are more likely to develop prostate cancer and are twice as likely to die from the disease.
However, two new clinical trials suggest, cutting-edge prostate cancer drugs that help extend life in the toughest cases might also be useful in fighting less aggressive tumors.
Two drugs that interfere with cancer’s ability to use testosterone for fuel, apalutamide (Erleada) and enzalutamide (Xtandi), are already approved for use against more advanced prostate tumors that don’t respond to regular therapy.
But these trials show that the drugs also can improve survival and slow progression in prostate cancers that do respond to regular therapy, which typically involves medication that halts production of testosterone.
Both clinical trials involved patients with